The case for & against
Bull & Bear analysis
Bearish
ORIC Pharmaceuticals (NASDAQ: ORIC) is a biotechnology company focused on developing innovative cancer therapies that aim to overcome drug resistance in tumors that are challenging to treat. With a diversified pipeline of compounds intended to address high unmet medical needs, ORIC seeks to provide first-in-class and potentially best-in-class solutions in oncology. The company is navigating a competitive landscape, marked by the recent discontinuation of ORIC 101 due to insufficient clinical efficacy, which challenges it to realize the potential of its promising pipeline.
Bull says
- ↑$280.4 M cash funds operations into 2H 2024
- ↑Three INDs filed (ORIC 533, 114, 944); data due H1 2023
- ↑Positive analyst revisions and high institutional ownership signal confidence
- ↑Stock broke above its 50-day MA with strong momentum
- ↑Focus on combination therapies (e.g., PLK4 for breast cancer) offering differentiation
Bear says
- ↓Q4 2021 net loss $22.8 M; 2021 expenses of $78.9 M highlight burn rate
- ↓High leverage and negative earnings yield signal valuation pressure
- ↓Discontinuation of ORIC 101 due to insufficient efficacy dents pipeline
- ↓Intense oncology competition heightens trial success requirements
- ↓Key trial outcomes in 2023 remain uncertain for valuation recovery
Investment themes with ORIC
Biotech↓ -3.20%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Earnings Call · Q4 2021 · Mgmt. Guidance
Updated 07-02-2026neutral
Transcript signals
Bull points
- We ended the year with $280.4 million in cash and investments.
- As a result of the discontinuation of ORIC 101, we now expect our cash runway to extend into the second half of 2024, which is well beyond the expected initial data disclosures from our three clinical programs in the first half of 2023.
- We're very proud of the team and pipeline that we've assembled here at ORIC.
Bear points
- we were not able to demonstrate evidence of sufficient clinical benefit on any of the efficacy endpoints.
- the outcomes seen in our study of ORAC101 with enzalutamide were insufficient to support continued development.
- we saw only one confirmed partial response in the ovarian cancer cohort and no objective responses in the PDAC cohort.
Read full transcript analysis ›